The new regulations, which govern the Patented Medicine Prices Review Board, will lower pharmaceutical industry profits by $2.9 billion over a decade, rather than the $8.8 billion anticipated previously.
At the same time, Canadians could end up with even more limited access to medications if a wholly public pharmacare plan fails to deliver a formulary as comprehensive as what private plans today offer.
Admin overload: Dr. Alykhan Abdulla argues we need scribes, we need more allied healthcare workers and we need more IT solutions in the second of a three-part series.